Pretzel’s innovative therapy to modulate mitochondrial function receives Series A funding
ADC评论
September 15, 2022
On September 12, Pretzel Therapeutics, a biotechnology company, announced the completion of a $72.5 million Series A financing to pioneer innovative therapies that modulate mitochondrial
